The average prevalence of сhronic heart failure in the adult population, according to the statistics of different countries, ranges from 1.5 % to 5.5 % and therefore the study of this problem and of finding new approaches to the treatment of сhronic heart failure is also still relevant at present. Objective is to show an innovative strategy in the treatment of сhronic heart failure, to show the benefits of using the combined drug sacubitril/valsartan (LCZ696) in comparison with the group of the mentioned above drugs for treating patients with сhronic heart failure and a reduced left ventricular ejection fraction, according to the results of a large randomized clinical research, based on its biochemical properties. Conclusions. The main positive effects of sacubitril and valsartan in patients with сhronic heart failure are associated with an increase in the amount of the natriuretic peptide and the simultaneous suppression by valsartan of the negative effects of angiotensin II. The indication for the use of the sakubitril / valsartan complex is сhronic heart failure (II-IV FC according to the NYHA classification) in patients with systolic dysfunction in order to reduce the risk of cardiovascular mortality and hospitalization for heart failure.